Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3901)
All Articles published online
|
Publishing Process of This Article
|
Feb 26, 2022 (publication date) through Aug 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Shan BB, Li Y, Zhao C, An XQ, Zhang QM. Efficacy of EGFR-TKI sequential therapy in patients with EGFR exon 19 insertion-positive non-small-cell lung cancer: A case report. World J Clin Cases 2022; 10(6): 1883-1888 [PMID: 35317151 DOI: 10.12998/wjcc.v10.i6.1883] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i6/1883.htm |
| Number | Citing Articles |
| 1 |
Yingying Jiang, Xiaoxu Fang, Yan Xiang, Tingwen Fang, Jingwen Liu, Kaihua Lu. Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review. Current Oncology 2023; 30(6): 5337 doi: 10.3390/curroncol30060405
|
| 2 |
William Shaffer, Ikei S. Kobayashi, Daniel Sentana-Lledo, Shriram Sundararaman, Meghan D. Lee, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi, Daniel B. Costa. EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors. Lung Cancer 2023; 181: 107250 doi: 10.1016/j.lungcan.2023.107250
|